The antiserum was produced against synthesized peptide derived from human IKK-beta. AA range:166-215

IKKβ Polyclonal Antibody detects endogenous levels of IKKβ protein.

IKBKB

Inhibitor of nuclear factor kappa-B kinase subunit beta

IKBKB ;
IKKB ;
Inhibitor of nuclear factor kappa-B kinase subunit beta ;
I-kappa-B-kinase beta ;
IKK-B ;
IKK-beta ;
IkBKB ;
I-kappa-B kinase 2 ;
IKK2 ;
Nuclear factor NF-kappa-B inhibitor kinase beta ;
NFKBIKB

The protein encoded by this gene phosphorylates the inhibitor in the inhibitor/NF-kappa-B complex, causing dissociation of the inhibitor and activation of NF-kappa-B. The encoded protein itself is found in a complex of proteins. Several transcript variants, some protein-coding and some not, have been found for this gene. [provided by RefSeq, Sep 2011],

Catalytic activity:ATP + [I-kappa-B protein] = ADP + [I-kappa-B phosphoprotein].,Function:Acts as part of the IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Also phosphorylates NCOA3.,PTM:Ubiquitination on 'Ser-163' modulates phosphorylation on C-terminal serine residues.,PTM:Upon cytokine stimulation, phosphorylated on Ser-177 and Ser-181 by MEKK1 and/or MAP3K14/NIK; which enhances activity. Once activated, autophosphorylates on the C-terminal serine cluster; which decreases activity and prevents prolonged activation of the inflammatory response.,PTM:Yersinia yopJ may acetylate Ser/Thr residues, preventing phosphorylation and activation, which blocks the I-kappa-B signaling pathway.,similarity:Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. I-kappa-B kinase subfamily.,similarity:Contains 1 protein kinase domain.,subunit:Component of the I-kappa-B-kinase (IKK) core complex consisting of CHUK, IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits. The IKK core complex seems to associate with regulatory or adapter proteins to form a IKK-signalosome holo-complex. Part of a complex composed of NCOA2, NCOA3, CHUK/IKKA, IKBKB, IKBKG and CREBBP. Part of a 70-90 kDa complex at least consisting of CHUK/IKKA, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14. Interacts with SQSTM1 through PRKCZ or PRKCI. Forms an NGF-induced complex with IKBKB, PRKCI and TRAF6. May interact with MAVS/IPS1. Interacts with NALP2. Interacts with TICAM1. Interacts with Yersinia yopJ. Interacts with FAF1; the interaction disrupts the IKK complex formation. Interacts with ATM. Part of a ternary complex consisting of TANK, IKBKB and IKBKG. Interacts with NIBP; the interaction is direct.,tissue specificity:Highly expressed in heart, placenta, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis and peripheral blood.,

Cytoplasm . Nucleus . Membrane raft . Colocalized with DPP4 in membrane rafts. .

Highly expressed in heart, placenta, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis and peripheral blood.

>>Antifolate resistance ;
>>MAPK signaling pathway ;
>>Ras signaling pathway ;
>>Chemokine signaling pathway ;
>>NF-kappa B signaling pathway ;
>>FoxO signaling pathway ;
>>mTOR signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>Apoptosis ;
>>Osteoclast differentiation ;
>>Toll-like receptor signaling pathway ;
>>NOD-like receptor signaling pathway ;
>>RIG-I-like receptor signaling pathway ;
>>Cytosolic DNA-sensing pathway ;
>>C-type lectin receptor signaling pathway ;
>>IL-17 signaling pathway ;
>>Th1 and Th2 cell differentiation ;
>>Th17 cell differentiation ;
>>T cell receptor signaling pathway ;
>>B cell receptor signaling pathway ;
>>TNF signaling pathway ;
>>Neurotrophin signaling pathway ;
>>Insulin signaling pathway ;
>>Adipocytokine signaling pathway ;
>>Type II diabetes mellitus ;
>>Insulin resistance ;
>>Non-alcoholic fatty liver disease ;
>>Alcoholic liver disease ;
>>Alzheimer disease ;
>>Epithelial cell signaling in Helicobacter pylori infection ;
>>Pathogenic Escherichia coli infection ;
>>Shigellosis ;
>>Salmonella infection ;
>>Yersinia infection ;
>>Chagas disease ;
>>Toxoplasmosis ;
>>Hepatitis C ;
>>Hepatitis B ;
>>Measles ;
>>Human cytomegalovirus infection ;
>>Influenza A ;
>>Human papillomavirus infection ;
>>Human T-cell leukemia virus 1 infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Herpes simplex virus 1 infection ;
>>Epstein-Barr virus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Coronavirus disease - COVID-19 ;
>>Pathways in cancer ;
>>MicroRNAs in cancer ;
>>Chemical carcinogenesis - reactive oxygen species ;
>>Pancreatic cancer ;
>>Prostate cancer ;
>>Chronic myeloid leukemia ;
>>Acute myeloid leukemia ;
>>Small cell lung cancer ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer ;
>>Lipid and atherosclerosis ;
>>Fluid shear stress and atherosclerosis